Rodero, BS, Martínez-Toledo, C, Nadal, E, Molina-Alejandre, M, Campelo, RG, Gil-González, A, Massuti, B, García-Grande, A, Dómine, M, Insa, A, Carpeño, JD, Vence, GH, Majem, M, Martinez-Marti, A, Megias, D, Lobato, D, Collazo-Lorduy, A, Calvo, V, Provencio, M, Cruz-Bermúdez, A. Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial). OncoImmunology. 2025; 14(1)DOI:10.1080/2162402X.2025.2513109. PMID:40468805. IF:6.300(Q1/2D).

Cerezuela-Fuentes, P, de la Rosa, CA, Crespo, G, Berciano-Guerrero, MA, Soria, A, Muñoz-Couselo, E, Castro, RL, Majem, M, de Miguel, PA, Manzano, JL, Bellido, L, Lecumberri, MJ, Subias, MC, Guzmán, JCV, Hernández, B, Espinosa, E, Puértolas, T, Sanz, LG, Martínez, JM, Abril, VP, Algarra, SM, Márquez-Rodas, I. Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study. MELANOMA RESEARCH. 2025; 35(6)DOI:10.1097/CMR.0000000000001062. PMID:40901826. IF:1.900(Q3/6D).

Hecht, JR, Park, YS, Tabernero, J, Lee, MA, Lee, SHY, Virgili, AC, van den Eynde, M, Fontana, E, Fakih, M, Asghari, G, So, JE, Stein, A, Dubreuil, O, Bodnar, L, He, CS, Wang, G, Smith, R, Eng, C, Saeed, A. Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial. LANCET. 2025; 406(10517)DOI:10.1016/S0140-6736(25)02025-2. PMID:41130252. IF:88.500(Q1/1D).

Fernández-Morata, J, Pollán, M, de Larrea-Baz, NF, Pachon-Olmos, V, García-Pérez, J, Castello, A, Sierra, MA, Lucas, P, Llobet, R, Stradella, A, Cantos, B, Cajal, TRY, Santisteban, M, Seguí, MA, Bertrán, AS, Granja, M, Camps-Herrero, J, Recalde, S, Nuñez-García, B, Verges, NC, Pérez-Gomez, B, Pastor-Barriuso, R, Lope, V. Mammographic density and breast cancer pathological subtypes by menopausal status and body mass index (vol 27, 187, 2025). BREAST CANCER RESEARCH. 2025; 27(1)DOI:10.1186/s13058-025-02169-5. PMID:41225573. IF:5.600(Q1/2D).

Simoes, AR, González, SC, Lopez-Doldan, MD, Duran, G, Fernández-Montes, A, Fernandez, MP, Fernandez, MS, Mata, JG, Paez, D, Riera, P, Guino, E, Lopez-Fernandez, L, de Santiago, BG, Aspiroz, EL, Rojas, A, Castells, A, Castellvi-Bel, S, Ponte, CR, Vymetalkova, V, Carracedo, A, Fernandez-Rozadilla, C. Novel approaches for the discovery of pharmacogenetic biomarkers of chemotoxicity in patients with colorectal cancer. BRITISH JOURNAL OF PHARMACOLOGY. 2025; 182(21)DOI:10.1111/bph.70051. PMID:40624839. IF:7.700(Q1/1D).

Isla, D, Zugazagoitia, J, Arriola, E, García-Campelo, R, Blanco, CM, Diz-Taín, MP, Lopez-Brea, M, Moreno-Vega, AL, León-Mateos, L, Oramás, J, Gutiérrez-Calderón, V, Majem, M, Sánchez-Hernández, A, Aguado, C, Alvarez-Cabellos, R, Massutí, B, Moreno, A, Fírvida-Pérez, JL, Valdivia, J, González-Cordero, M, Zafra-Poves, M, Dómine, M, Garcia-Navalon, FJ, Villanueva, N, Provencio, M, Juan-Vidal, O, Rivas-Corredor, C, García, MEO, Palmero, R, López-Castro, R, Carcereny, E, Lechuga, JL, Domínguez, M, Callejo, A, Paz-Ares, L. Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial. LUNG CANCER. 2025; 209DOI:10.1016/j.lungcan.2025.108763. PMID:41033130. IF:4.400(Q1/2D).

Soler, G, Grávalos, C, Rivera, F, Safont, MJ, Virgili, AC, Valladares-Ayerbes, M, Ferreiro-Monteagudo, R, Ortiz-Morales, MJ, Polo-Marques, E, Kornusova-Bersheva, I, Soustre, E, Yao, WY, Élez, E. Predictive factors of efficacy for FTD/TPI plus bevacizumab in refractory metastatic colorectal cancer patients: a subanalysis of the Spanish cohort from the SUNLIGHT phase III trial. Clinical & Translational Oncology. 2025; 27(11)DOI:10.1007/s12094-025-03907-z. PMID:40338282. IF:2.500(Q3/6D).

Cortellini, A, Garbo, E, La Cava, G, Citarella, F, Santo, V, Brunetti, L, Pinato, DJ, Naidoo, J, Loza, M, Genova, C, Gettinger, S, Kim, SY, Jayakrishnan, R, El Zarif, T, Russano, M, Pecci, F, Di Federico, A, Montrone, M, Owen, DH, Signorelli, D, Li, MJ, Camerini, A, Halmos, B, Vincenzi, B, Metro, G, Yendamuri, S, Grossi, F, Josephides, E, Tomasik, B, Giusti, R, Bria, E, Sebastian, M, Rost, M, Acker, F, Landi, L, Mazzoni, F, Morabito, A, Leonetti, A, Cantini, L, Mountzios, G, Kalvapudi, S, O'Reilly, D, Karapanagiotou, E, Monnet, I, Baena, J, Macerelli, M, Majem, M, Piedra, A, Cortinovis, DL, Tonini, G, Minuti, G, Mezquita, L, Gorria, T, Beninato, T, Lo Russo, G, Prelaj, A, De Giglio, A, Biello, F, Nana, FA, Dingemans, AMC, Aerts, JG, Ferrara, R, Abu Hejleh, T, Takada, K, Naqash, AR, Garassino, MC, Wakelee, HA, Nassar, A, Ricciuti, B, Soda, P, Caruso, CM, Guarrasi, V. Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression = 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity. LUNG CANCER. 2025; 209DOI:10.1016/j.lungcan.2025.108799. PMID:41108882. IF:4.400(Q1/2D).